Entecavir Cuts Hep B Reactivation in Diffuse Large B-Cell Lymphoma

This article originally appeared here.
Share this content:
Entecavir Cuts Hep B Reactivation in Diffuse Large B-Cell Lymphoma
Entecavir Cuts Hep B Reactivation in Diffuse Large B-Cell Lymphoma

(HealthDay News) -- Entecavir is more efficacious than lamivudine for preventing hepatitis B virus (HBV) reactivation among patients who are seropositive for the hepatitis B surface antigen with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy treatment. These findings have been published in the Dec. 17 issue of the Journal of the American Medical Association.

He Huang, M.D., from Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues compared the efficacy of entecavir and lamivudine in preventing HBV reactivation in patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy treatment. Patients were seropositive for the hepatitis B surface antigen and had normal liver function. They were randomized to daily 0.5 mg entecavir (61 patients) or 100 mg lamivudine (60 patients) beginning one week before R-CHOP initiation.

The researchers found that the incidence of HBV-related hepatitis was significantly lower in the entecavir group than in the lamivudine group (0 versus 13.3 percent; P = 0.003). The incidence of HBV reactivation was also significantly lower in the entecavir group (6.6 versus 30.0 percent; P = 0.001), as was chemotherapy disruption (1.6 versus 18.3 percent; P = 0.002).

"If replicated, these findings support the use of entecavir in these patients," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths